2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.09 (Poster) Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US

PP01.09 (Poster) Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US

Pdf Summary

This document presents the findings of a study that aimed to describe the treatment patterns and outcomes of patients with metastatic non-small-cell lung cancer (mNSCLC) who experienced disease progression after receiving platinum-doublet chemotherapy (PDC) and anti-PD(L)1 therapy, either concurrently or sequentially. The study used a retrospective, non-interventional physician panel-based medical chart review to collect de-identified patient-level data from physicians in the US who had experience treating mNSCLC. The most common subsequent treatment regimens for patients after disease progression were non-platinum chemotherapy, anti-PD(L)1 monotherapy, PDC in combination with a VEGF(R) inhibitor, and non-platinum chemotherapy in combination with a VEGF(R) inhibitor. The overall median overall survival (OS) was 9.8 months, with 6- and 12-month OS rates of 71.4% and 43.8%, respectively. The median time-to-treatment discontinuation (TTD) was 5.8 months, with 6- and 12-month TTD rates of 45.1% and 12.6%, respectively. The overall median real-world progression-free survival (rwPFS) was 6.9 months, with 6- and 12-month rwPFS rates of 57.2% and 34.0%, respectively. The findings of this study highlight the need for more effective treatment options for patients with mNSCLC who experience disease progression on anti-PD(L)1 and PDC therapy. However, it should be noted that the generalizability of these findings to the overall practice of oncologists/pulmonologists and to outside the US may be limited. Additionally, assessments of disease progression in real-world settings may vary and may not be consistently applied across patients and physician practices.

Asset Subtitle

Stephen Liu

Keywords

metastatic non-small-cell lung cancer

treatment patterns

outcomes

platinum-doublet chemotherapy

anti-PD(L)1 therapy

retrospective study

subsequent treatment regimens

overall survival

time-to-treatment discontinuation

real-world progression-free survival